It is safe to say that what happens following the consolidation will determine the future of Imugene, whether it goes on to fantastic data that leads to an FDA approval, or it doesn't provide the necessary data to do so.
Should the first premise occur those that have hung on through thick and thin will be rewarded, if not many investors will lose on a risky investment that they can only blame themselves for.
Yes, it's true to say that some exuberance has come from management that never came to fruition, and no one can predict outcomes from a market as fluid as this one, especially at the moment.
There are still many shareholders, (myself included) that believe in the science as we have constantly reminded to do, and even a smaller cohort that remain confident in management decision making.
I am sure that PH & LC cannot fathom why the shareprice is in the toilet, given the lack of bad news and the promising data that has been presented.
Not even the most pessimistic of shareholders could have predicted a shareprice so low considering the potential of the IP and the long protections attached to the method of treatments.
I remain optimistic yet sadly wounded by the current circumstances and feel for everyone else caught in this nightmare.
DYOR opinion only
IMU Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)